original clinical study Purpose: to determine the role of a single cycle of topical azithromycin in preventing long-term trachoma complications in children from an area with endemic trachoma.
T rachoma is a keratoconjunctivitis that is caused by Chlamydia trachomatis. contact with objects such as towels and clothing of affected individuals, body secretions, and flies can spread trachoma.
1,2 trachoma is the most common cause of preventable blindness in the world, accounting for 3.6% of total blindness worldwide.
3-5 untreated trachoma can cause trachomatous trichiasis, scarring, and corneal opacity, leading to adult blindness. 6 traditionally, the antibiotic regimen used to treat trachoma has been tetracycline 1% ointment, twice daily for 6 weeks or intermittently for 6 months. However, compliance has been unsatisfactory. the World Health organization (WHo) more recently recommended a single oral dose of azithromycin (20 mg/kg in children or 1 g in adults) as an effective way to treat trachoma. However, the inappropriate use of oral azithromycin could lead to modification of the bacterial strains responsible for causing trachoma, making them resistant to treatment. this sentiment has been strongly expressed internationally. 7, 8 the WHo previously set the year 2020 as a target date for controlling trachoma at a significantly lower level so as to ensure that blindness resulting from trachoma would no longer remain an international public health concern. also effective orally, azithromycin in the form of 1.5% eye drops is now a new and innovative treatment modality for infectious trachoma. 9 in this study, patients with active trachoma treated with a single regimen of azithromycin 1.5% eye drops, given twice daily for 3 days, were followed up for 3 years. the long-term effects of this therapy were documented for the first time in an endemic area. materials and methods a longitudinal cohort study was conducted by the department of community ophthalmology, al-shifa trust Eye Hospital, rawalpindi, Pakistan, from august 1, 2011, to July 31, 2014. Ethical approval for this study (Ethical committee astEH#5157) was provided by the Ethical committee of al-shifa trust Eye Hospital, rawalpindi, Pakistan (chairperson Prof Wajid ali Khan) on February 12, 2011. the study conformed to the principles embodied in the declaration of Helsinki.Written informed consent was taken from the legally acceptable representatives of the studied children. two hundred sixty (n = 260) children aged from 1 to 10 years were diagnosed as having active trachoma based on WHo classification.
10 these children were identified out of a survey of 8600 children from 7 villages in Punjab, Pakistan. the villages were in an area with endemic trachoma and were ready to participate in the current study. these villages were selected based on a previous trachoma rapid assessment survey conducted by alshifa trust Eye Hospital, Pakistan using standard WHo protocol for a trachoma prevalence survey. 11 two hundred thirty-eight (n = 238) children with active trachoma were enrolled in the current study. they were aged from 1 to 10 years with trachomatous inflammation (tF) + trachomatous inflammation-follicular (ti0) or tF + ti+ (trachomatous inflammation-follicular and intense) on the simplified WHo grading system. twenty-two (n = 22) children with trichiasis or corneal opacity, ocular infection, ocular abnormality, organic amblyopia, fibrosis with palpebral deformation, hypersensitivity to azithromycin eye drops, immunosuppressive conditions, or use of systemic or topical medication other than the investigational product before the study were excluded from the current study. 10 none of the studied patients had a history of taking any topical or systemic medications for any eye infection other than those prescribed by the authors of the current study.
all the children were given azithromycin 1.5% eye drops twice daily for 3 consecutive days at basic health units on day 1; whereas on days 2 and 3, our team administered the dose at the children's homes. no active interventions for the s, F, and E components of the saFE (surgery, antibiotic, Facial cleanliness, Environment) strategy of trachoma control were included in the current study. the children were followed up for the presence or absence of active trachoma along with the presence or absence of ocular complications associated with trachoma at 1 year and 3 years. the ocular complications included conjunctival scarring, trichiasis, distichiasis, corneal opacity, and fibrosis, along with palpebral deformation and cicatricial entropion. the examiner (t.a.) was the same at baseline and throughout follow-up.
the children included in the study were examined by everting the upper eyelid and examining each eye using a 2.5 binocular magnifying loupe. the patients were evaluated using the WHo grading system. 10 the examiner changed gloves after examining each patient. the efficacy and safety of azithromycin 1.5% eye drops on trachoma infection were assessed by the percentage of clinical cure in children with clinically active trachoma after long-term follow-up (1 year and 3 years). adverse events were recorded at each visit. the children who tested positive for trachoma at 1-year follow-up were again given azithromycin 1.5% eye drops twice daily for 3 consecutive days. However, they were only followed up for the presence or absence of trachoma-related ocular complications for the remaining study period. similarly, the children who tested positive for trachoma at 3 years' followup were again given azithromycin 1.5% eye drops twice daily for 3 consecutive days to treat the active trachoma (Fig. 1) . results there were 238 children included in the current study of a total of 8600 children who were screened for active trachoma; all were aged from 1 to 10 years at baseline and had active trachoma (table 1) .
there were 170 male and 68 female children. two hundred fourteen (90%) were present at 1-year follow-up with 10% dropout, and 178 (75%) were present at 3-year follow-up with 25% dropout. at 1 year, there were 50 children, or 23%, with active trachoma (32 males and 18 females). at 3 years, there were 20 children, or 11%,with active trachoma (12 males and 8 females). active trachoma was minimized from 100% at baseline to 11% at the end of 3 years. twelve children (n = 12) remained persistently positive throughout 3 years. one hundred thirty-two (n = 132) children remained persistently negative for disease after a single treatment with topical azithromycin twice daily for 3 consecutive days. the reinfection rate was 4% (table 2) . no active interventions for the s, F, and E components of the saFE strategy of trachoma control were included in the current study.
none of the legally acceptable guardians of the studied children refused treatment. none of the studied patients developed trachoma-related ocular complications during the study period. no ocular or systemic adverse effects were reported in the current study during the study period. disCussion the epidemiological situation of trachoma in an endemic area can be assessed by 2 means: clinical grading and nucleic acid amplification tests.
12 the simplified WHo trachoma grading system was used in the current study to determine the role of a single cycle of topical azithromycin in preventing long-term trachoma-related ocular complications in children from an endemic area. this study also determined the effectiveness, safety, and tolerability of topical azithromycin 1.5% eye drops for reducing the prevalence of active trachoma over a long follow-up period.
oral azithromycin (20 mg/kg) is the most commonly used drug for trachoma mass treatment campaigns. clinical cure rates with oral azithromycin are very variable. 9 (table 3) . in 2 districts in niger, the prevalence of tF among children decreased from 62.3% and 49.5% to 7.6% and 6.7%, respectively, in 3 years. 9 a reduction of 92.4% in the prevalence of tF/ti was recorded in Mali over a 3-year interval after oral azithromycin. 16 cochereau et al have also discussed the efficacy and safety of azithromycin 1.5% eye drops for treating active trachoma in children in Pakistan. they showed that the use of azithromycin 1.5% eye drops, twice daily for 3 days, showed similar efficacy to oral azithromycin (20 mg/kg) in treating active trachoma at 2 months after treatment.
8 However, as the study conducted by cochereau et al had a shorter follow-up period, it did not ascertain if measures against reinfection affected the clinical cure rate over a long-term period. Moreover, Ejere et al 19 showed that face washing alone or in combination with topical tetracycline had no beneficial effects in reducing active trachoma over a 12-month period. in view of the observations of cochereau and Ejere, the authors of the current study used azithromycin 1.5% eye drops in children with active trachoma only and followed them over a period of 3 years for trachoma-related ocular complications and reinfection.
trachoma follicular is a widely used and a validated tool for grading trachoma in a clinical setting.
11 a grade of trachoma follicular was the clinical end point of the cure in the current study. High clinical cure rates of 77% and 89% over 1-year and 3-year periods, respectively, were recorded with azithromycin 1.5% eye drops in the current study. the findings of the current study show that azithromycin 1.5% eye drops yield similar results to oral azithromycin (20 mg/kg) in treating active trachoma in children over long-term follow-up. 9, 16 the reinfection rate in the current study was 4%. it remains debatable how only 4% of the studied children with active trachoma at baseline were reinfected and 89% were clinically cured at 3-year follow-up after the use of topical azithromycin 1.5% eye drops only at baseline without any other measures against reinfection. Victor et al 20 discussed the role of genetic polymorphism and highlighted the importance of immunogenetic variations in individuals that influence the reinfection rate and the development of blinding trachomatous disease. they also showed 20 that ocular C. trachomatis infections provide serovar-specific immunity, which may explain the low reinfection rate in the current study. it is generally believed that serovars a, B, and c are normally found in developing countries where trachoma is endemic. 20 another longitudinal study in an endemic trachoma population showed that duration of disease and infection shortened as the age of the studied population increased. repeated exposure to C. trachomatis in endemic areas increases protective passive immunological responses.
21 Faal et al 22 discussed the role of age-related modulation and expression of protective cytokines like iFn (gamma), ido, and il-10 against C. trachomatis infections, which increase with age. in addition to possible serovar-specific immunity and immunogenetic variations, the increased expression of these protective cytokines may also have contributed to the low reinfection rate in the current study after topical azithromycin 1.5% eye drops only.
the topical treatment was widely accepted by the population in the current study. no ocular or systemic adverse effects were recorded over the study period. none of the studied patients developed trachoma-related ocular complications during the study period. as the treatment was administered directly by health care personnel, the entire studied population received the treatment. to ensure an uninterrupted supply of eye drops and high coverage, mobilization of resources and coordination among relevant health authorities was mandatory.
the need for topical treatment of trachoma was stressed in a working paper that was presented at the WHo alliance for the global Elimination of Blinding trachoma by the year 2020 (gEt 2020) meeting. 7 this paper also discussed the advantages of azithromycin 1.5% eye drops over oral azithromycin and topical tetracycline. 7 inappropriate use of oral azithromycin is associated with bacterial resistance and systemic adverse effects in children. 7, 8 similarly, compliance with topical tetracycline in children is poor because it is difficult to apply and causes discomfort and blurring of vision.
23 in view of these limitations and the results of the current study, treatment with azithromycin 1.5% eye drops, twice daily for 3 days, is an effective, rapid, safe, innovative, and convenient option for treating active trachoma in children and preventing trachoma-related blindness worldwide.
therefore, azithromycin 1.5% eye drops represent an alternative to the WHo's reference treatment.
8 this topical treatment can be used as a supplementary tool in treating active trachoma in children and pregnant women. 9 the main drawback of the current study is that it is not a randomized controlled study against oral azithromycin. additionally, owing to various economic and logistic constraints, polymerase chain reaction could not be used for the diagnosis of trachoma.
the findings of the current study show that a single cycle of topical azithromycin is an effective and safe option for treating active trachoma in children in endemic areas. this study also documented that a single cycle of topical azithromycin can be used to prevent trachoma-related ocular complications in an endemic area over long-term follow-up. 
